Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary Angioedema

Aygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results

Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM

Journal of Allergy and Clinical Immunology

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP

Clinical & Experimental Allergy